Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.5%

3 terminated/withdrawn out of 55 trials

Success Rate

90.3%

+3.8% vs industry average

Late-Stage Pipeline

35%

19 trials in Phase 3/4

Results Transparency

0 of 28 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

25(52.1%)

Phase 3

14(29.2%)

Phase 4

5(10.4%)

N/A

3(6.3%)

Phase 2

1(2.1%)

48Total

Phase 1(25)

Phase 3(14)

Phase 4(5)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (55)

Showing 20 of 55 trials

NCT03317743Phase 1Completed

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Role: collaborator

NCT05845489Phase 4Recruiting

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

Role: collaborator

NCT06635226Phase 1Recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

Role: lead

NCT06063291Phase 1Completed

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

Role: lead

NCT05604287Phase 1Terminated

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Role: lead

NCT02792088Phase 3Completed

Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

Role: lead

NCT05663879Phase 1Unknown

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

Role: lead

NCT04982705Phase 1Unknown

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Role: lead

NCT05259020Phase 1Unknown

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

Role: lead

NCT04218162Phase 3Completed

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

Role: lead

NCT04249908Phase 1Unknown

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Role: lead

NCT01937806Phase 3Unknown

Phase 3 and Extensional Study of Besifovir

Role: lead

NCT04185090Phase 1Unknown

To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

Role: lead

NCT04202536Phase 4Unknown

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

Role: lead

NCT03761082Completed

Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy

Role: lead

NCT04001400Phase 3Completed

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Role: collaborator

NCT03363269Phase 2Completed

Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease

Role: lead

NCT03964103Not ApplicableCompleted

qQ-lab Daily-IBS for Irritable Bowel Syndrome

Role: lead

NCT03937648Phase 1Unknown

Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers

Role: lead

NCT03907228Not ApplicableUnknown

Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis

Role: lead